B+
Bull case
25%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-04-28 · RankAlpha Sentiment Codex
KZIA
Kazia TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Primary-source evidence supports a cautious upside case built around several real 2026 shots on goal: Q2 FDA path-forward feedback in GBM, 2H neuro-oncology readouts, and 2H breast-cancer efficacy/biomarker updates. March 2026 materials also cited roughly US$46 million of cash, no debt, and runway into 2029 excluding additional or expanded trials, which helps support continued execution [#IR-2026-03-27].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +11.7.
What can break
Clinical evidence remains early and fragile, with the January 2026 TNBC update based on a very small number of patients and no mature randomized efficacy readout yet.
Momentum
73
Value
49
Sentiment
63
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $12.00 · Bull $19.00 · Bear $5.50Analysis 2026-04-28; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-28 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $31.20
Why
Momentum73 · Δ7d +7.8
Value49 · Δ7d 0.0
Sentiment63 · Δ7d +11.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +11.7.
Contradictions & invalidation
- • Clinical evidence remains early and fragile, with the January 2026 TNBC update based on a very small number of patients and no mature randomized efficacy readout yet.
- • Coverage is thin and the peer set is loose, so external validation of the thesis is limited and volatility around company-controlled updates may remain elevated.
- • The thesis is still monitoring-style because the strongest positive clinical signal disclosed so far is based on only two evaluable trial patients plus one expanded-access case, while losses and operating cash burn continue and the company has also put an at-the-market facility in place through Leerink.
Catalyst clock
2026-06-30
FDA path-forward update for paxalisib in glioblastoma
Lead driver: Sentiment · See AI snapshot
Momentum
73
9% active weight
Current posture
7d trendImproving
Δ7d
+7.8
Δ21d
+0.8
Value
49
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Sentiment
63
62% active weight
Current posture
7d trendImproving
Δ7d
+11.7
Δ21d
+22.8
Why this grade
Composite grade C. Momentum 73.3 / Value 49.3 / Sentiment 62.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-28. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-04-28 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-04-28 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$154.95M
Beta
1.79
Shares Out
11.43M
P/E (TTM) · Derived
-3.7
P/S (TTM)
802.17
P/FCF (TTM) · Derived
-2.26
Rev YoY
-96.3%
EPS YoY
+96.8%
Gross Margin
+64.0%
Op Margin
-21258.8%
Net Debt
-$2.59M
Current Ratio
2.87
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data